(1-(tert-Butoxycarbonyl)-1H-indol-2-yl)boronic acid, 98.0%, 1g

Ethyl 2-cyclopentylideneacetate, 95.0%, 5g

Methyl 1H-pyrrolo[3,2-c]pyridine-4-carboxylate, 95.0%, 1g

(R)-�-Homoalanine hydrochloride, 97.0%, 10g

N-(tert-Butoxycarbonyl)-D-alanine>98.0%(HPLC)(T)5g

1-Methylpyrrolidine-3-carboxylic acid, 97.0%, 250mg

6-Hydroxy-2-(1-methylethylidene)-1-benzofuran-3(2H)-one, 95.0%, 500mg

2-[3-(2-hydroxyethyl)-4-oxo-3,4-dihydrophthalazin-1-yl]acetic acid, 98%, 250mg

2-Hydroxy-3-methyl-5-nitropyridine, 95.0%, 10g

trans-4-Methylcyclohexylamine>98.0%(GC)25g

2-Phenylthiazole-4-carboxylic acid, 97.0%, 5g

Infinity corrected plan phase S100x/1.25 objective. Working distance 0.18 mm

2-Bromo-5-chlorophenol, 95.0%, 25g